BIO 2025 Report: U.S. Bioscience Industry Policy Guide for State Growth

Readers searching “Pdf the us bioscience industry 2022” usually want the BIO/CSBA state policy series and its economic companion data. Current BIO/CSBA releases plus BLS projections still show a multi-trillion-dollar footprint and faster demand for scientific R&D roles that states compete to host.

Key Takeaways

• BIO and CSBA reported more than $3.2 trillion in U.S. bioscience industry output for 2023 in their December 2024 economic-impact release.
• BLS May 2024 medians include $103,650 for biochemists/biophysicists and $106,950 for bioengineers/biomedical engineers.
• Scientific R&D employment is projected to grow 8.7% from 2024 to 2034, with biotechnology and medical research among demand drivers.
• Policy levers that matter for growth include R&D incentives, biomanufacturing cost relief, and workforce pipelines—not a single federal grant alone.

What does BIO/CSBA say about industry scale?

On December 2, 2024, BIO and CSBA announced via PR Newswire new national and state-level data on the U.S. bioscience industry’s economic performance. The release states that industry economic impact, measured as overall output, totaled more than $3.2 trillion in 2023.

That series is the quantitative companion many states use when arguing for bioscience incentives. Later BIO/CSBA “best practices” editions extend the conversation from size to policy design—R&D credits, manufacturing tax treatment, and early-stage capital tools—but economic-impact figures above are taken from the PR Newswire release, not from secondary blogs.

How do BLS wages frame the talent pitch?

State growth strategies often hinge on high-skill job quality. BLS Occupational Outlook Handbook medians for May 2024 include:

• Biochemists and biophysicists: $103,650 median pay; 35,600 jobs in 2024; 6% projected growth for 2024–34.
• Bioengineers and biomedical engineers: $106,950 median; 22,200 jobs; 5% projected growth.
• Microbiologists: $87,330 median; about 20,700 jobs; 4% projected growth (BLS OOH).

Those wage and outlook numbers help policymakers explain why bioscience clusters compete for talent with software and finance markets.

Where is employment growth concentrated?

BLS’s Monthly Labor Review overview of 2024–34 projections highlights research and development in the physical, engineering, and life sciences as a fast-growing industry, projecting 8.7% employment growth. The article ties demand to health- and biotechnology-related research, including pharmaceuticals, medical equipment, and diagnostics.

Occupations called out for related demand include medical scientists (except epidemiologists), biochemists and biophysicists, and bioengineers and biomedical engineers. For state strategy, that is a signal to pair capital incentives with training pipelines that feed scientific R&D employers.

What a practical state policy stack looks like

Across BIO/CSBA economic messaging and BLS labor data, the operable stack is familiar: refundable or transferable R&D tax support for pre-revenue firms, sales-tax relief on manufacturing and lab equipment, SBIR/STTR matching where states choose to amplify federal awards, and community-college or university pathways into technician and scientist roles. Exact state counts of each incentive change year to year and should be verified in the current legislative session before budgeting.

How investors should read the policy stack

For company diligence, state incentive menus matter most when they change cash timing: refundable R&D credits can fund payroll before revenue, while equipment sales-tax exemptions cut capex for first manufacturing suites. BLS wage data help stress-test whether a local hiring plan is competitive against coastal hubs paying above national medians.

Public bioscience company revenue growth cited in BIO/CSBA materials should be separated from early-stage venture conditions. A strong public-revenue year can coexist with selective private financing, so policy ROI arguments should not assume every local startup will raise on public-market terms.

What remains outside these sources

Neither the PR Newswire economic release nor BLS OOH tables by themselves prove which single incentive has the highest ROI in a given state. Site-selection decisions still turn on wet-lab inventory, permitting timelines, and local venture density that national aggregates cannot capture.

Older “Pdf the us bioscience industry 2022” editions remain useful for trend context, but 2023–2024 output and 2024–34 BLS projections should be preferred for current budget memos. Always confirm the edition year on the cover page before citing a state program as active law.

Related NovaPharma coverage

• Biotech coming of age: market analysis
• Biotech’s coming of age: AI, capital efficiency and China
• Weight Loss Medications in 2026: GLP-1 Market Shift

Frequently Asked Questions

How large is U.S. bioscience economic output in BIO/CSBA reporting?

In a December 2, 2024 PR Newswire release, BIO and CSBA reported that U.S. bioscience industry economic impact exceeded $3.2 trillion in overall output for 2023.

What do BLS data show for core bioscience occupations?

BLS Occupational Outlook figures for May 2024 show median pay of $103,650 for biochemists/biophysicists, $106,950 for bioengineers/biomedical engineers, and $87,330 for microbiologists.

Which workforce trend supports state bioscience policy?

BLS projects research and development in the physical, engineering, and life sciences to grow 8.7% from 2024 to 2034, with strong demand tied to health and biotechnology research.

Primary Sources

1. PR Newswire — BIO/CSBA bioscience economic impact (Dec 2, 2024)
2. BLS — Biochemists and biophysicists Occupational Outlook
3. BLS Monthly Labor Review — 2024–34 employment projections overview